Safeguard Scientifics, Inc. (SFES)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -2 | -2 | ||||||
| Net profit | $m | -38 | 27 | -14 | -10 | -10 | 2 | - | - |
| EPS reported | $ | 0.10 | 1.25 | ||||||
| Operating cashflow per share | $ | 0.00 | 0.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | 0.00 | 0.00 | ||||||
| Free cash flow | $m | - | -3 | ||||||
| Net debt | $m | -9 | -5 | ||||||
| Book value equity | $m | 12 | 6 | ||||||
| Book value per share | $ | 0.69 | 0.37 | ||||||
| Number of shares | m | 16.72 | 16.72 | ||||||
| DPS (TTM paid) | $ | 1.40 | 1.40 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 8.05 | 0.33 | ||||||
| P/B LTM | x | 1.17 | 2.16 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | 0.00 | -5.06 | ||||||
| EV/EBITDA LTM | x | -2.82 | -2.50 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | +12.42% | +303.03% | ||||||
| FCF Yield | % | 0.00% | -19.76% | ||||||
| Quality | |||||||||
| ROE | % | +14.93% | +131.34% | ||||||
| ROIC | % | -17.77% | -6.73% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | +350.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 5.28 | 97.84 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +1.50% | +0.76% | ||||||
| Net debt/Equity | x | -0.76 | -0.78 | ||||||
| Gross debt/equity | x | 0.02 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Safeguard Scientifics, Inc., a former private equity and venture capital firm, is no longer actively seeking new investments. Historically, the firm specialized in a broad range of financing activities, including providing capital for company expansion and growth, facilitating management buyouts, executing recapitalizations, driving industry consolidations, and supporting corporate spin-offs. Their investment scope covered both early and growth-stage companies. Typically, Safeguard Scientifics participated in Series A, B, or C funding rounds, with an opportunistic approach to seed-stage investments. Their primary sector focus spanned technology, financial services, and healthcare. Within the technology sphere, their interests were diverse, encompassing areas such as software-as-a-service (SaaS), adtech, digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (FinTech), cloud computing, mobile, social platforms, big data, in-memory computing, and select business services. For these tech ventures, they considered companies requiring up to $25 million in capital. In the healthcare sector, the firm directed its investments towards molecular and point-of-care diagnostics, various medical devices, regenerative medicine, broader medical technology, digital health solutions, healthcare technology, specialized pharmaceuticals, and chosen healthcare services. Geographically, Safeguard Scientifics invested across the entire United States, with a particular emphasis on the Mid-Atlantic region, and also extended its reach into Southeastern Canada. Financial commitments for growth equity financing generally ranged from $5 million to $25 million, while early-stage financings typically saw investments between $5 million and $10 million. The firm's investment strategy often targeted a variety of capital structures, including self-funded (bootstrapped) companies, corporate divisions or business units, and venture capital-backed entities seeking a growth partner. Safeguard Scientifics aimed to be the largest stakeholder in its portfolio companies, typically acquiring an ownership stake between 20% and 50%, though they were flexible and might occasionally take either a majority or a smaller interest. A strong preference existed for companies possessing proprietary technology and intellectual property. Furthermore, the firm routinely sought a Board seat in its invested companies. Founded in 1953 as Lancaster Corporation, the company adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is located in Radnor, Pennsylvania, with an additional presence in Weston, Massachusetts.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Safeguard Scientifics, Inc. (SFES)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Safeguard Scientifics, Inc., a former private equity and venture capital firm, is no longer actively seeking new investments. Historically, the firm specialized in a broad range of financing activities, including providing capital for company expansion and growth, facilitating management buyouts, executing recapitalizations, driving industry consolidations, and supporting corporate spin-offs. Their investment scope covered both early and growth-stage companies. Typically, Safeguard Scientifics participated in Series A, B, or C funding rounds, with an opportunistic approach to seed-stage investments. Their primary sector focus spanned technology, financial services, and healthcare. Within the technology sphere, their interests were diverse, encompassing areas such as software-as-a-service (SaaS), adtech, digital media, the Internet of Everything (IoE), advanced security solutions, predictive analytics, machine learning, artificial intelligence, enterprise software, technology-enabled services, internet/new media, financial technology (FinTech), cloud computing, mobile, social platforms, big data, in-memory computing, and select business services. For these tech ventures, they considered companies requiring up to $25 million in capital. In the healthcare sector, the firm directed its investments towards molecular and point-of-care diagnostics, various medical devices, regenerative medicine, broader medical technology, digital health solutions, healthcare technology, specialized pharmaceuticals, and chosen healthcare services. Geographically, Safeguard Scientifics invested across the entire United States, with a particular emphasis on the Mid-Atlantic region, and also extended its reach into Southeastern Canada. Financial commitments for growth equity financing generally ranged from $5 million to $25 million, while early-stage financings typically saw investments between $5 million and $10 million. The firm's investment strategy often targeted a variety of capital structures, including self-funded (bootstrapped) companies, corporate divisions or business units, and venture capital-backed entities seeking a growth partner. Safeguard Scientifics aimed to be the largest stakeholder in its portfolio companies, typically acquiring an ownership stake between 20% and 50%, though they were flexible and might occasionally take either a majority or a smaller interest. A strong preference existed for companies possessing proprietary technology and intellectual property. Furthermore, the firm routinely sought a Board seat in its invested companies. Founded in 1953 as Lancaster Corporation, the company adopted the name Safeguard Scientifics, Inc. in 1981. Its main office is located in Radnor, Pennsylvania, with an additional presence in Weston, Massachusetts.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free